Please login to the form below

Not currently logged in
Email:
Password:

Lutathera

This page shows the latest Lutathera news and features for those working in and with pharma, biotech and healthcare.

AAA board presses go on $3.9bn Novartis takeover

AAA board presses go on $3.9bn Novartis takeover

With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards

Latest news

  • Novartis to buy French radiopharma specialist AAA for $3.9bn Novartis to buy French radiopharma specialist AAA for $3.9bn

    The Swiss pharma giant said this morning that the deal would help strengthen its cancer therapy businesses, adding an approved radiopharmaceutical drug - Lutathera (177Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours

  • AAA’s orphan drug Lutathera wins EU green light AAA’s orphan drug Lutathera wins EU green light

    AAA’ s orphan drug Lutathera wins EU green light. The first-in-class drug treats adults with GEP-NET. ... LAR. Buono added: “We will continue to work closely with the respective health authorities in each country to make Lutathera widely available.”

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    Advanced Accelerator Applications secured a recommendation for Lutathera (lutetium [177Lu] oxodotreotide) - for the treatment of gastro-entero-pancreatic neuroendocrine tumours - and Ipsen got the nod for Xermelo (telotristat ethyl) as a

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics